Oncodesign Precision Medicine S.A

Business and Financial Review • Dec 12, 2023

PRESS RELEASE

TP ICAP Midcap initiates coverage of Oncodesign Precision Medicine with a "Buy" recommendation

Dijon (France), December 12, 2023, at 6:00pm CET– Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares.

In its initiation study entitled "Identify the Effective Therapeutic Route"", TP ICAP Midcap began covering the stock with a "Buy" recommendation and valued the Company at €2.75 per share.1

About Oncodesign Precision Medicine (OPM)

Oncodesign Precision Medicine (OPM), the result of the transfer of Oncodesign's Biotech and AI activities, is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers.

OPM's innovative technologies are (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix® for the design and selection of macrocyclic small molecule kinase inhibitors and (iii) Promethe for the design and selection of radiolabeled biological molecules for systemic radiotherapy.

From these technologies, OPM has built a portfolio of therapeutic products. A first drug candidate based on the Nanocyclix® technology entered the clinical phase in 2022, in partnership with SERVIER (which exercised its option for an exclusive worldwide license on the program) to treat Parkinson's disease. OPM-101 is OPM's second candidate to enter the clinic, in the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier to discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology. In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase I. Finally, OPM has a significant portfolio of early-stage projects with Nanocyclix® and Promethe in oncology. With this portfolio of molecules and diversified therapeutic targets, OPM's mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital cluster, OPM has 25 employees.

More info at: oncodesign.com

NewCap Investor Relations Mathilde Bohin / Alban Dufumier Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu

NewCap

Media Relations Arthur Rouillé Tel: +33 (0)1 44 71 00 15 oncodesign@newcap.eu

¹ This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe, securities in France, Europe, the United States or any other country. The provision of a financial analysis production and dissemination service has been agreed between Oncodesign Precision Medicine and TP ICAP Midcap.